Dual effect of nitric oxide donors on cyclooxygenase-2 expression in human mesangial cells

J Am Soc Nephrol. 1999 May;10(5):943-52. doi: 10.1681/ASN.V105943.

Abstract

Nitric oxide (NO) is emerging as a key regulator of gene expression, capable of playing either positive or negative roles. The results of this study indicate that NO exerts a dual effect on cyclooxygenase-2 (COX-2) expression in human mesangial cells (HMC). Treatment of HMC with NO synthase inhibitors attenuated interleukin-1beta (IL-1beta/tumor necrosis factor-alpha (TNF-alpha)-elicited COX-2 protein and mRNA expression, suggesting a positive role of endogenous NO on COX-2 induction. However, NO donors (sodium nitroprusside [SNP] and S-nitroso-N-acetylpenicillamine [SNAP]) amplified cytokine-elicited COX-2 expression at early time points of treatment (up to 8 h for mRNA and up to 24 h for protein expression), but were inhibitory at later times. Oligonucleotide decoy experiments confirmed the importance of nuclear factor kappaB (NF-kappaB) activation for COX-2 induction by IL-1beta/TNF-alpha. Treatment with N(G)-nitro-L-arginine methyl ester (L-NAME) did not affect initial activation of NF-kappaB by IL-1beta/TNF-alpha, but unveiled an inhibitory effect of NO generation on NF-kappaB activity after 4 h. In HMC supplemented with SNP, cytokine-induced NF-kappaB activation was potentiated at early times of induction (5 to 15 min), but inhibited at later times (1 to 4 h), suggesting a dual effect of NO donors on NF-kappaB activation. Interestingly, IkappaBalpha protein levels followed a reciprocal pattern of expression: IkappaBalpha levels were lower at early times of induction in NO donor-supplemented cells; however, after 1 h of treatment, IkappaBalpha levels became higher than in cells treated only with cytokines. In the presence of SNP, cytokine-elicited IkappaBalpha mRNA induction was initially delayed, but was amplified at later times. These changes in IkappaBalpha expression could contribute to the dual effects of NO donors on NF-kappaB activation and COX-2 expression in HMC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • DNA-Binding Proteins / metabolism
  • Enzyme Induction / drug effects
  • Enzyme Inhibitors / pharmacology
  • Glomerular Mesangium / cytology
  • Glomerular Mesangium / drug effects
  • Glomerular Mesangium / enzymology*
  • Glomerular Mesangium / metabolism
  • Humans
  • I-kappa B Proteins
  • Interleukin-1 / pharmacology
  • Isoenzymes / drug effects
  • Isoenzymes / metabolism*
  • Membrane Proteins
  • NF-kappa B / genetics
  • NF-kappa B / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Donors / pharmacology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitroprusside / pharmacology*
  • Oligonucleotides / genetics
  • Oligonucleotides / pharmacology
  • Penicillamine / analogs & derivatives*
  • Penicillamine / pharmacology
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • S-Nitroso-N-Acetylpenicillamine
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • I-kappa B Proteins
  • Interleukin-1
  • Isoenzymes
  • Membrane Proteins
  • NF-kappa B
  • Nitric Oxide Donors
  • Oligonucleotides
  • Tumor Necrosis Factor-alpha
  • Nitroprusside
  • S-Nitroso-N-Acetylpenicillamine
  • Nitric Oxide Synthase
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Penicillamine
  • NG-Nitroarginine Methyl Ester